TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAS

00529

Luz Martin Carbonero[1], Angela Gil-Martin[2], Teresa Aldámiz-Echevarría[3], Vicente Estrada[4], Carlos Barros[5], Rebeca Font[6], Pablo Ryan[7], Carmen Quereda[8], Beatriz Alvarez[9], Rafael Mican[1], Juan Berenguer[3], JorgeVergas[4], Maria Luisa Montes[1], Juan Carlos Lopez Bernaldo[3], for Madrid-CoRe Study Group. [1]La Paz University Hospital, Madrid; [2] Subdireccion General de Farmacia, Madrid; [3]HospitalGeneral Universitario Gregorio Marañón, Madrid; [4]Hospital Universitario Clínico San Carlos, Madrid; [5]Hospital Universitario de Móstoles, Madrid; [6]Hospital Universitario 12 de Octubre, Madrid; [7]Hospital Universitario Infanta Leonor, Madrid; [8]Hospital Ramón y Cajal, Madrid; [9]FundacionJimenez Diaz, Madrid. Spain.

BACKGROUND

- Sofosbuvir/Velpatasvir/Voxilaprevir is recommended as first-line retreatment option for patients with chronic hepatitis C (HCC) who had previously failed to other direct-active antiviral agents (DAA)[1].
- It has demonstrated high effectiveness in both clinical trials and real-life studies[2,3].
- However, data among people living with HIV (PVIH) HCV coinfected are scarce.

METHODS

- RUA-HCV is a prospective and mandatory registry of adults (≥18 years) undergoing therapy with DAAs for HCV infection in the region of Madrid since Nov 2014, These data are exported to Madrid Coinfection Registry (Madrid-Core) created to determine the effectiveness and safety of all-oral DAAs in PHIV-HCV coinfected[4].
- In this analysis, patients included in Madrid-Core, ≥18 years, re-treated with SOF/VEL/VOX and who were scheduled to finish treatment before Jan 1,2021, were selected.
- Scheduled treatment was SOF/VEL/VOX 1 qd 12 weeks.
- Sustained virologic response (SVR) was assessed at 12 weeks after the end of planned treatment.
- Results are given by intention-to-treat (ITT) (all patients are included) and per-protocol analysis (PP) in which patients with no response data or discontinuations were excluded for the analysis.

RUA-VHC Prescriptors: Achécar Justo, Linette María; Aguirre Losada, Alberto Ángel; Ahumada, Adriana; Alarcón del Amo, Cristina; Albillos Martínez, Agustín; Aldámiz Echevarría Lois, María Teresa; Alonso López, Sonia; Avarez Álvarez, Beatriz; Arias Milla, Ana; Arias Rivera, María Luisa; Arocena Aranguren, Carlos; Arponen, Sari; Arranz Caso, José Alberto; Bañares Ca izares, Rafael; Baños Pérez, Isolina; Barranco Cao, Raquel; Barrio Antoranz, José; Barros Aguado, Carlos Antonio; Beceiro Pedreño, Inmaculada; Bejerano Domínguez, Alicia; Belda Bilbao, Luis Miguel; Beltrán Castaño, Rocío; Benítez Gutiérrez, Laura María; Berenguer Berenguer, Juan; Bernardino De la Serna, José; Borrego Rodríguez, Gloria; Cabello Clotet, Noemí; Cabello Ubeda, Alfonso; Calleja Panero, José Luis; Calvo Fernández, Santiago; Calvo Hernández, Rocío; Canalejo Castrillero, Eduardo; Carrión Alonso, Gemma; Casado Osorio, Josék; Castellano Tortajada, Gregorio; Castillo Grau, Pilar; Castro Urda, José Luis; Cervero Jiménez, Miguel; Chico Álvarez, Inmaculada; Clemente Ricote, Gerardo; Comas Redondo, Carmen; Correa Abanto, Lizbeth Milagros; Costero Pastor, Ana Bel n; Cuenca Alarcón, Francisca; Cuenca Morón, Beatriz; Cuevas Tascón, Guillermo; De Guzmán García-Monge, María Teresa; De La Poza Gómez, Gema; de Lagarde Sebastián, María; De Miguel Prieto, Julio; Del Portillo Rubí, Álvaro; Del Pozo Prieto, David; del Río Izquierdo, Mar a; Devesa Medina, María José; Díaz De Santiago, Alberto; Díaz Fontenla, Fernando; Díaz Sánchez, Antonio; Domingo Serna, Daniel; Domínguez García, Nuria; Duca, Ana María; Erdozain Sosa, Jose Carlos; Esteban Fernández, Francisco Javier; Estrada Pérez, Vicente; Fernández Amago, María Teresa; Fernández Rodíguez, Conrado;Fernández Vázquez, Inmaculada; Ferrere González, Federico; Flores Fernández, Virginia; Fortún Abete, Jesús; García Benayas, María Teresa; García Buey, Luisa Consuelo; García de Aguinaga, M Luisa; García González, Miguel; García Mayor, María de los Á ngeles; García Sánchez, Araceli; García-Samaniego Rey, Francisco; Gaspar Alonso-Vega, Gabriel; Gea Rodríguez, Francisco; Gijón Vidaurreta, Paloma; Gil Ares, Fernando; Gimeno García,Alejandra; Gómez Rubio, Mariano; Góngora López, Andrea; González Alonso, María Raquel; González Alonso, Mar a Rosario; Gonz lez Guirado, Agustina; Gonz lez Moreno, Leticia; Gonz lez-Ruano P rez, Patricia; G rgolas Hern ndez, Miguel De; Gotuzzo Altez, Luis Ricardo; Graus Morales, Javier; Guti rrez Garc a, M Luisa; Herráquez Camacho, César Augusto; Hervás Gómez, Rafael; Hidalgo Aguirre, Lorena; Hinojosa Mena-Bernal, Juan; Huertas Velasco, Mar a Antonia; Ibáñez Pinto, Alberto; Iborra Herrera, Jerónimo; Izquierdo Rubio, Sonia; Jaime Sánchez, Belén; Jusdado Ruiz-Capillas, Juan José Lo lacono, Oreste; López Bernaldo de Quirós, Juan Carlos; López Martín, María del Carmen; Losa García, Juan Emilio; Lozano Maya, María del Mar; Malmierca Corral, Eduardo; Manzano Alonso, María Luisa; Marcos Rojas Rodríguez de Quesada, Jorge; Maroto Castellanos, Maite; Martín Algíbez, Ana María; Martín Carbonero, Luz; Martínez Consuegra, Jos Antonio; Matarranz del Amo, Mariano; Melero Bermejo, Jos Antonio; Men ndez Mart nez, Mar a Antonia; Merino Morales, Francisco; Miralles Martín, Pilar; Monsalvo Arroyo, Raquel; Montero Hern ndez, María Carmen; Montes Ramírez, M Luisa; Montilla De Mora, Pedro; Moran Ortiz De Sol rzano, Marta; Moreno Celda, Victoria; Moreno Guillen, Santiago; Moreno Núñez, Leonor; Moreno Sánchez, Diego; Moreno Zamora, Ana Mar a; Mu oz G mez, Raquel; Navarrete Garc a, Elena; Navas Elorza, Enrique; Novella Mena, Mar a; N ez Orantos, Mar a Jos ; Olivares Valles, Ana; Oliveira Mart n, Antonio; Ortiz Duran, Mar a; Padilla Ortega, Belén; Parras Vazquez, Francisco; Peñalver Cifuentes, Rafael; Pérez Álvarez, Mónica; Pérez Ellas María Jesús; Pérez Molina, Jose Antonio; Pérez Quero, Jose Luis; Pérez Rial, Gabriel; Pérez Valderas, María Dolores; Pérez Valero, Ignacio; Piqueras Alcohol, Belén; Polo Lorduy, Benjamín Arturo; Porres Cubero, Juan Carlos; Poves Martínez, Elvira; Pulido Ortega, Federico; Quereda Rodríguez-Navarro, Carmen; Real Martínez, Yolanda; Rincón Rodríguez, Diego; Rivero Fernández, Miguel; Rodríguez Rodríguez, Raquel; Romero Cristóbal, Mario; Romero Portales, Miriam; Rubio García, Rafael; Ruiz Giardín, José Manuel; Ryan Murúa, Pablo; Salcedo Plaza, Magdalena; San Martín López, Juan Víctor; Sánchez Gómez, Argeme; Santos Gil, Ignacio; Sanz Moreno, Julián; Sanz Rojas, Patricia; Serrano Heranz, Regino; Serrano Villar, Sergio Daniel; Soto Fernández, Susana; Suarez García, Inés María; Tejedor Bravo, Marta; Téllez Molina, María Jesús; Terrancle Juan, Ignacio; Torres Perea, Rafael; Troya García, Jesús; Valbuena González, Marta; Valencia Ortega, Eulalia; Valer López-Fando, María Paz; Varela Silva, Andrés I; Vegas Serrano, Ana; Velasco Arribas, María; Vergas García, Jorge; Víctor Palomares, Virginia; Villa Poza, Jose Carlos; Vivancos Gallego, Mar a Jes s.

RESULTS



OUTCOME 12 WEEKS AFTER END OF TREATMENT	
Sustained Virologic Response	45
Relapse	2
Discontinuation	2
Lost to follow-up	7





FLOW-CHART

4834 PLHIV-HCV Start treatment in Madrid <1/Jan/2021 → 56 started SOF/VEL/VOX

BASELINE CHARACTERISTICS (N=56)	
GENDER (MALE/FEMALE)	42/4 (92.9%/7.1%)
AGE (median; IQR)	51.9 (47.7-54.5)
GENOTIPE G1a G1b G3 G4 Other/mixed/unknown	 30 (56.6%) 4 (7.1%) 7 (12.5%) 9 (16.1%) 6 (10.7%)
Log HCV-RNA	6.2 (5.2-6.7) UI/ml
Fibrosis F0-1 F2 F3 F4 (compensated/decompensated)	 28 (59%) 9 (16.1%) 9 (16.1%) 10 (17.9%) (7/3)

BASELINE CHARACTERISTICS II (n=56)	
HIV TREATMENT - 2NRTI+1 INSTI - 2NRTI+1 NNRTI - 2NRTI+1PI - No HIV treatment - Other/unknown	 22 (39.3%) 9 (16.1%) 5 (8.9%) 3 (5.3%) 17 (30.3%)
CD4 cell count	563 (425-800)
HIV-RNA < 50 Cp/ml	39 (73.2%)
Previous HCV treatment SOF/LED 2D/3D EBR/GRZ SOF/DCV GLE/PIB Other	 28 (59%) 5 (9.4%) 5 (9.4%) 5 (9.4%) 5 (9.4%) 8 (14.2%)

NRTI: Nucleoside analogue reverse transcriptpase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; INSTI: Integrase inhibitors; PI:Protease Inhibitors; SOF: sofosbuvir; LED: ledipasvir; 2D Ombitasvir+Paritaprevir+ritonavir; 3D: Ombitasvir+Paritaprevir/ritonavir+Dasabuvir; DCV:Daclatasvir; GLE:glecaprevir; PIB:pibentrasvir.

CONCLUSIONS

- SOF/VEL/VOX is highly effective for HCV treatment in PLHIV previously failing to DAA regimens.
- Effectiveness was confirmed across all genotypes and in the presence of cirrhosis.

REFERENCES

1. AASLD-IDSA guidelines. Hepatology 2020;71:686-721.
2. Bourliere M et al; N Engl J Med 2017;376:2134-46.
3. Belpeiro P et al; J Viral Hepat 2019;26:580-590.
4. Berenguer J et al; Hepatology 2018;68:32-47.

Author contact: lmcarbonero@gmail.com